

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Ward JI, Cherry JD, Chang S-J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. *N Engl J Med* 2005;353:1555-63.

**Supplementary Table -Summary of Subject allocation and follow-up
Consort data**

- I. Approached/Accessed for eligibility = 3,450 (estimated*)
- II. Excluded / not eligible = 66 (estimated*)
- III. Refusals = 603 (estimated*)
- IV. Enrolled, randomized, immunized = 2,781 (est 81%)
- V. Comparison of study groups (see table 1)
 - A. aP group (N=1391)**
 1. No (%) with 6 mon follow-up = 1363 (98%)
 2. No (%) with 12 mon follow-up = 1313 (94%)
 3. No (%) with 18 mon follow-up = 1,002 (72%)
 4. Total patient-years of follow-up = 2421
 5. No (%) with some loss of follow-up = 82 (6%)
 6. No (%) discontinued prematurely = 154 (11%)
 7. Analysis of all above available data
 - B. Hep A control group (N =1390)**
 1. No (%) with 6 mon follow-up = 1366 (98%)
 2. No (%) with 12 mon follow-up = 1325 (95%)
 3. No (%) with 18 mon follow-up = 1018 (74%)
 4. Total patient-years of follow-up = 2444
 5. No (%) with some loss of follow-up = 70 (5%)
 6. No (%) discontinued prematurely = 161 (12%)
 7. Analysis of all above available data

*Study initiated in 1997. The estimates shown above are based upon detailed enrollment data at study coordinating site (largest subject contributor, 15% of subjects at all 8 national study sites).